Related Experiment Videos

[Hypertrophic cardiomyopathy showing no 123I-BMIPP myocardial accumulation with type I CD36 deficiency]

K Watanabe1, S Miyajima, Y Kusano

  • 1Niigata College of Pharmacy.

Insights

This study investigates a patient with hypertrophic cardiomyopathy (HCM) and no myocardial uptake of 123I-beta-methyl-p-iodophenylpentadecanoic acid (123I-BMIPP). Researchers found type 1 CD36 deficiency may explain the lack of 123I-BMIPP uptake in the heart.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart condition.
  • Myocardial fatty acid metabolism is crucial for cardiac function.
  • 123I-beta-methyl-p-iodophenylpentadecanoic acid (123I-BMIPP) is used to assess myocardial fatty acid uptake.

Observation:

  • A 57-year-old male with HCM presented with chest oppression and shortness of breath.
  • 201Tl SPECT showed regional increased accumulation in the ventricular septum.
  • No myocardial accumulation of 123I-BMIPP was observed in this patient.

Findings:

  • The patient was diagnosed with type 1 CD36 deficiency.
  • CD36 is a key transporter for myocardial uptake of long-chain fatty acids.
  • This deficiency correlates with the absence of 123I-BMIPP myocardial uptake.

Implications:

  • CD36 deficiency may be a contributing factor to impaired myocardial fatty acid metabolism in HCM.
  • This finding could refine the interpretation of 123I-BMIPP SPECT in patients with cardiac conditions.
  • Further research is warranted to explore the role of CD36 in cardiac pathophysiology and diagnostic imaging.

Related Concept Videos